Galunisertib Plus Gemcitabine vs. Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0246-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

Neoadjuvant Treatment With Gemcitabine Plus Nab-Paclitaxel Versus Surgery First for Pancreatic Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

A Phase I Study of Imexon Plus Gemcitabine as First-Line Therapy for Advanced Pancreatic Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2014English

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Intra-Arterial and Tumor-Targeted Infusion of Gemcitabine in Patients With Unresectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Cetuximab Plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Metastatic Pancreatic Cancer: A Multicentre Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2009English

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine

Oncology Letters
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy